Research from Water Tower Research, Water Tower Research

Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Research from Water Tower Research

Equity Research Firm

Thematic (Sector/Industry)

United states Consumer discretionary / Thematic (Sector/Industry)

<ul><li>Affordability is an important condition for broad-based accessibility to psychedelic-assisted therapy (PAT), both now (ketamine) and in the future (MDMA, psilocybin, et al.).</li><li>This makes the evolution of payor coverage as critical a part of the development of PAT as the clinical trial outcomes and the progression toward a more accommodative regulatory environment.</li><li>Current payor coverage for ketamine-assisted therapy (KAT) is inconsistent at best.</li></ul>

Affordability is an important condition for broad-based accessibility to psychedelic-assisted therapy (PAT), both now (ketamine) and in the future (MDMA, psilocybin, et al.).This makes the evolution of payor coverage as critical a part of the development of PAT as the clinical trial outcomes and the progression toward a more accommodative regulatory environment.Current payor coverage for ketamine-assisted therapy (KAT) is inconsistent at best.

Shroom Shmooz: Thoughts on Pathways to More Robust Payor Coverage for PAT